Date published: 2026-7-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

IGF-1 Receptor α/β/IGF1R Lentiviral Activation Particles (m): sc-421057-LAC

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
  • IGF-1 Receptor α/β/IGF1R Lentiviral Activation Particles (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
  • IGF-1 Receptor α/β/IGF1R Lentiviral Activation Particles (m) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
  • Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
  • gRNAs encoded by IGF-1 Receptor α/β/IGF1R Lentiviral Activation Plasmid (m) and IGF-1 Receptor α/β/IGF1R Lentiviral Activation Plasmid (m2) target distinct regulatory regions of the Igf1r promoter. One or both designs may be available
  • Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: IGF-1 Receptor α/IGF1R Antibody (G-5): sc-271606
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    IGF-1 Receptor α/β/IGF1R Lentiviral Activation Particles (m)

    sc-421057-LAC
    200 µl
    $455.00

    IGF-1 Receptor α/β/IGF1R Lentiviral Activation Particles (m2)

    sc-421057-LAC-2
    200 µl
    $455.00

    Mouse Igf1r encodes IGF-1 Receptor α/β (IGF1R), a transmembrane receptor tyrosine kinase that binds IGF-1 and IGF-2 to regulate growth factor sensing, cell survival, and metabolic homeostasis. Ligand-dependent autophosphorylation triggers recruitment of IRS adaptor proteins and activation of PI3K–AKT–mTOR and RAS–RAF–MEK–ERK signaling, coordinating proliferation, differentiation, and resistance to cellular stress. IGF1R signaling interfaces with insulin receptor pathways and modulates apoptosis, cell-cycle progression, and cytoskeletal dynamics. Dysregulation of this axis is studied in oncogenic transformation, therapy resistance mechanisms, and metabolic phenotypes in vivo, making Igf1r a common node for pathway mapping and functional genomics.

    IGF-1 Receptor α/β/IGF1R Lentiviral Activation Particles (m) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient Igf1r upregulation across a broader range of human cell types.

    IGF-1 Receptor α/β/IGF1R Lentiviral Activation Particles (m) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the Igf1r transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous IGF-1 Receptor α/β/IGF1R expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native Igf1r genomic locus and regulatory architecture.

    The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.